COCP
Cocrystal Pharma, Inc.
There isn't enough reported data to score COCP yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
COCP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
COCP's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
COCP PE Valuation
COCP has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
COCP Forward outlook
There aren't enough analyst estimates for COCP to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
COCP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.75 | +$0.48 |
| Q1 2026 | -$0.72 | +$0.84 |
| Q4 2025 | -$0.78 | +$0.94 |
| Q3 2025 | -$0.93 | +$0.89 |
| Q2 2025 | -$1.23 | +$0.51 |
| Q1 2025 | -$1.56 | +$0.06 |
| Q4 2024 | -$1.72 | +$0.15 |
| Q3 2024 | -$1.82 | +$0.19 |
COCP is still losing money, but far less than before: $0.75 per share over the past year, against $20.16 at its worst in mid-2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over COCP on earnings quality, reporting a profit while its opponent remains loss making.
COCP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2020 | $510K | +27% |
| Q3 2020 | $489K | -0.6% |
COCP's revenue has slid since its 2020 peak: $105,000 last quarter, down 81% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -3032% | N/A |
| Q1 2026 | -1047% | N/A |
| Q4 2020 | -287% | +11634 points |
| Q3 2020 | -554% | -187 points |
| Q2 2020 | -623% | N/A |
| Q1 2020 | -425% | N/A |
| Q4 2019 | -11922% | N/A |
| Q3 2019 | -367% | N/A |
COCP's operating margin was −3032% last quarter, down 2410 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over COCP in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over COCP on profitability, with a higher operating margin.
COCP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$1.7M | +$1.4M |
| Q4 2024 | -$3.2M | +$225K |
| Q3 2024 | -$5.1M | -$2.4M |
| Q2 2024 | -$3.7M | +$1.9M |
| Q1 2024 | -$4.5M | -$1.4M |
| Q4 2023 | -$3.4M | +$1.5M |
| Q4 2022 | -$4.9M | -$2M |
| Q4 2021 | -$2.9M | -$548K |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with COCP at up 27%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
COCP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +2K shares |
| 1 year | +36% | +3.6M shares |
| 3 years | +37% | +3.7M shares |
| 5 years | +132% | +7.8M shares |
COCP has 14M diluted shares, up 36% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over COCP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
COCP Net Leverage
COCP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
COCP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.6 | Neutral |
| Stochastic | 36.0 | Neutral |
COCP's weekly RSI is 45 (neutral) and its Stochastic is 36 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
COCP PE vs Healthcare Sector
COCP has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
COCP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.05 | 5.7% below |
| 20 week MA | $1.06 | 6.6% below |
| 50 week MA | $1.09 | 9.2% below |
| 100 week MA | $1.34 | 26% below |
| 200 week MA | $1.69 | 41% below |
COCP is in a downtrend: it's below all five of its weekly moving averages, and 41% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over COCP on trend strength, trading above more of its moving averages.
COCP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.40 | $18.6 | +244% |
| 2021 | $18.6 | $8.76 | -53% |
| 2022 | $8.76 | $1.97 | -78% |
| 2023 | $1.97 | $1.72 | -13% |
| 2024 | $1.72 | $3.09 | +80% |
| 2025 | $3.09 | $0.97 | -69% |
| 2026 YTD | $0.97 | $0.99 | +2.1% |
COCP's yearly returns have swung widely, from +244% in 2020 to −78% in 2022. It's up 2.1% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over COCP on returns for 2026, with the stronger performance.